- Business Partners
A solid basis for high quality
In 1947, Dr Wilhelm Benend was the first to synthesise a new active substance named sodium pentosan polysulfate (NaPPS), which quickly became popular with doctors and patients thanks to its excellent properties in numerous indications.
Two years later, he established a small pharmaceutical company in the south of Munich – Dr. Benend KG – which is now managed by the second generation of owners under the name bene-Arzneimittel GmbH.
In 1959, bene introduced the pain and fever medicine paracetamol to Germany, under the name ben-u-ron®. To this day, ben-u-ron® accompanies millions of patients worldwide throughout their lives, from birth to advanced age.
Today, bene sells a balanced range of innovative preparations on the German pharmaceuticals market – and worldwide in more than 35 countries. Some 100 employees at the Munich site strive to achieve consistent quality and are essential to our medium-sized company’s success.
Milestones: 65 years of bene success
The European Commission announced EU approval for elmiron®. With the Marketing Authorisation for elmiron®, bene-Arzneimittel has Europe's first approved drug therapy for the treatment of bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition. This disease pattern is also known as interstitial cystitis (IC).
Opening of a newly constructed high-bay storage in Olching, near Munich.
Dr Günter Auerbach is the new managing director of bene-Arzneimittel. The brothers Drs Harald and Helmut Benend, owners of the company and its managing directors for many years, move to the advisory board.
ben-u-ron® comfort is developed for easier and more hygienic suppository insertion in the youngest patients – the suppository already includes the lubricant Vaseline.
With ben-u-ron® direkt, a direct granulate to be taken without water, paracetamol from bene-Arzneimittel is now available in a new, contemporary dosage form.
bene-Arzneimittel opens its first subsidiary in Lisbon, Portugal: bene-farmaceutica.
The newly introduced quality management system according to the requirements of EN ISO 13485:2003/AC:2007 is certified by TÜV.
bene expands its analgesic range by the ibuprofen-containing ib-u-ron® suppositories.
Establishment of bene pharmaChem GmbH & Co. KG. The subsidiary just outside Munich is responsible for manufacturing the active substance sodium pentosan polysulfate (NaPPS).
In collaboration with paediatricians, ben-u-ron® 75 mg suppositories are developed and launched on the German market. Now optimally dosed treatment is available even for new-borns.
The sons of the company founder, Dr Harald Benend and Dr Helmut Benend, take over company management. Under their leadership, a medium-sized company develops but maintains its “large family company” feel.
At the beginning of the year, the unique rectal capsule “Klismacort” is launched with the ingredient prednisolone for treating croup syndrome.
Change in company name from bene-Chemie GmbH to bene-Arzneimittel GmbH.
bene-Chemie GmbH celebrates its 25-year anniversary. In the same year, a record result of more than DM 10 million is achieved. Exports exceeded domestic sales for the first time.
Establishment of the company bene-Chemie GmbH, which takes over the manufacture and sales of finished medicinal products and the active substances of Dr. Benend K.G. Sigrun and Dr Wilhelm Benend remain its sole owners until 1995.
Topping out ceremony of construction part I in Herterichstraße in Munich.
In addition to the pharmaceutical Thrombocid®, sodium pentosan polysulfate (NaPPS) is also sold as a separate substance.
In autumn, the success story of ben-u-ron® starts with the launch of the tablet dosage form. Later, suppositories for infants and children and the syrup are added to the product range.
Market launch of Tacholiquin®
The company Dr. Wilhelm Benend K.G. disposes of more than 7 preparations. In addition to the classic Thrombocid® , the company sells the pharmaceuticals Depot-Thrombocid® , Stypturon® , Angifin® and Telepaque® and the hand disinfectant pHisoHex®.
Initial contacts are established with partners abroad. In subsequent years, sales partnerships are established in the Netherlands, Austria, Argentina, Spain, Italy, Switzerland and many more countries.
The company building in Memlingstraße in Munich is completed.
Dr Benend files a trademark application for the name “Thrombocid" with the German Patent Office. After entry into the trademark register, Thrombocid is legally protected as a brand.
On 22 June 1949, Dr W. Benend establishes Dr. Wilhelm Benend K.G. : Sales of sodium pentosan polysulfate (NaPPS) start in Germany.
Dr Wilhelm Benend receives his doctorate from the Faculty of Natural Sciences Munich on 22 May with the overall grade “summa cum laude”.